PMC:7195088 / 19288-19594 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"666","span":{"begin":42,"end":50},"obj":"Species"},{"id":"776","span":{"begin":7,"end":17},"obj":"Chemical"},{"id":"777","span":{"begin":208,"end":227},"obj":"Chemical"},{"id":"778","span":{"begin":231,"end":241},"obj":"Chemical"},{"id":"779","span":{"begin":245,"end":256},"obj":"Chemical"},{"id":"780","span":{"begin":260,"end":278},"obj":"Chemical"},{"id":"781","span":{"begin":282,"end":293},"obj":"Chemical"},{"id":"928","span":{"begin":56,"end":64},"obj":"Disease"}],"attributes":[{"id":"A666","pred":"tao:has_database_id","subj":"666","obj":"Tax:9606"},{"id":"A776","pred":"tao:has_database_id","subj":"776","obj":"MESH:C000606551"},{"id":"A777","pred":"tao:has_database_id","subj":"777","obj":"MESH:C558899"},{"id":"A778","pred":"tao:has_database_id","subj":"778","obj":"MESH:C086979"},{"id":"A779","pred":"tao:has_database_id","subj":"779","obj":"MESH:D002738"},{"id":"A780","pred":"tao:has_database_id","subj":"780","obj":"MESH:D006886"},{"id":"A781","pred":"tao:has_database_id","subj":"781","obj":"MESH:D053139"},{"id":"A928","pred":"tao:has_database_id","subj":"928","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or wit"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":175,"end":180},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or wit"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T95","span":{"begin":56,"end":64},"obj":"Disease"}],"attributes":[{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or wit"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T97","span":{"begin":157,"end":160},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"}],"text":"1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or wit"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T186","span":{"begin":7,"end":17},"obj":"Chemical"},{"id":"T187","span":{"begin":208,"end":227},"obj":"Chemical"},{"id":"T188","span":{"begin":208,"end":217},"obj":"Chemical"},{"id":"T189","span":{"begin":218,"end":227},"obj":"Chemical"},{"id":"T190","span":{"begin":231,"end":241},"obj":"Chemical"},{"id":"T191","span":{"begin":245,"end":256},"obj":"Chemical"},{"id":"T192","span":{"begin":260,"end":278},"obj":"Chemical"},{"id":"T193","span":{"begin":282,"end":293},"obj":"Chemical"}],"attributes":[{"id":"A186","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A187","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A188","pred":"chebi_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A190","pred":"chebi_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A191","pred":"chebi_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A192","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A193","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"}],"text":"1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or wit"}

{"project":"LitCovid-sentences","denotations":[{"id":"T133","span":{"begin":66,"end":119},"obj":"Sentence"},{"id":"T134","span":{"begin":120,"end":191},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or wit"}